A young university student whose repeated symptoms of stomachache, nausea, vomiting, and weight loss were dismissed by ...

This combination has “the potential to become a new standard first-line treatment” for well-differentiated grade 1/2 gastroenteropancreatic neuroendocrine tumors with poor prognostic factors ...

If approved, Cabometyx® would be the first and only systemic therapy approved in the European Union for previously treated ...

These are neuroendocrine carcinomas (NECs). Grade . This is about cell division and growth rate. To describe this, you might hear the terms mitotic rate or Ki67%. The higher the mitotic rate or Ki67 % ...

Novel framework for response evaluation criteria in grade 1/2 neuroendocrine tumors (RECIN) following [177Lu]Lu-DOTATATE therapy: post-hoc analysis of the phase 2 LuCAP trial, European Journal of ...

A phase 3 trial establishes 177Lu-dotatate plus long-acting octreotide as a new first-line treatment for patients with high-grade gastroenteropancreatic neuroendocrine tumors.

A phase 1 trial combines immunotherapy and an oncolytic virus for high-grade neuroendocrine tumors, aiming to enroll 36 patients by 2030. The trial evaluates Opdivo, Yervoy, and Seneca Valley ...

There are 3 grades of neuroendocrine tumours (NETs) – grade 1, 2 and 3a: Grade 1 cancers grow slowly. They are low grade. Grade 2 grow at a moderate pace (between 1 and 3). ... European Neuroendocrine ...

A clinical trial for patients with high-grade neuroendocrine tumors is now open for enrollment at Sylvester Comprehensive Cancer Center. The new trial will test the novel combination of ...

A clinical trial for patients with high-grade neuroendocrine tumors is now open for enrollment at Sylvester Comprehensive Cancer Center, part of the University of Miami Miller School of Medicine.

1. Exelixis announces U.S. FDA approval of Cabometyx (cabozantinib) for patients with previously treated advanced neuroendocrine tumors. News release. Exelixis. March 26, 2025. Accessed March 26 ...